Melipramin

Imipramine Hydrochloride, the active ingredient in Melipramin, is a tricyclic antidepressant presented as an oral tablet for oral use. It treats major depressive disorder and related conditions in adults.

GNH USA supplies Melipramin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imipramine Hydrochloride is a tricyclic antidepressant that modulates monoamine neurotransmission and is indicated for several psychiatric and urological conditions.

- Major depressive disorder: alleviates depressive symptoms and improves mood. - Depressive episodes: reduces severity and duration of episodic depression. - Panic disorder: decreases frequency and intensity of panic attacks. - Enuresis: helps control nighttime urinary leakage in children.

Imipramine Hydrochloride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dry mouth: reduced salivation leading to discomfort. - Constipation: slowed gastrointestinal motility. - Drowsiness: increased sedation or fatigue. - Weight gain: increased appetite and body weight.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, potentially life‑threatening. - Seizures: risk of convulsive episodes. - Severe hypotension: marked drop in blood pressure. - Agranulocytosis: dangerous reduction in white blood cells.

When prescribing Imipramine Hydrochloride, several precautions should be observed to ensure patient safety.

- Cardiac assessment: evaluate history of heart disease before initiation. - Suicidal monitoring: watch for emergence or worsening of suicidal thoughts. - Discontinuation: avoid abrupt cessation to prevent withdrawal symptoms. - Elderly use: start at low dose and monitor for anticholinergic effects. - Hepatic impairment: adjust dose in patients with liver dysfunction. - Store at below 25°C: keep in the original packaging, protect from moisture.

Imipramine Hydrochloride interacts with several drug classes; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: risk of severe hypertensive crisis. - Selective serotonin reuptake inhibitors: increased serotonin syndrome risk. - Linezolid: potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: additive anticholinergic side effects. - CNS depressants: enhanced sedation and drowsiness. - CYP2D6 inhibitors: may raise imipramine plasma levels.